Examiner: O'NEILL, MARISOL ANN

Tech Center 1600 • Art Units: 1633

This examiner grants 53% of resolved cases

Analysis

Marisol Ann O'Neill is an examiner in Art Unit 1633 and Tech Center 1600. She has 32 resolved cases with an allowance rate of 53.1 percent. The median days to allowance is 1256, which indicates a long duration for successful prosecution. Practitioners should prepare for a timeline that spans many days in Tech Center 1600.

The interview lift is a significant 68.2 percent. This massive increase over the 53.1 percent baseline allowance rate indicates that interviews are an extremely effective tool for advancing applications. For the 32 cases resolved, the 1256-day median pendency is a key factor to consider. Practitioners should prioritize interviews, as the 68.2 percent lift suggests they are a primary driver of success in Art Unit 1633. Navigating the 1256-day process is much more likely to result in an allowance if verbal engagement is utilized.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

53.1%

Allow Rate

-6.9% vs TC avg

Total Applications

+68.2%

Interview Lift

1256

Avg Prosecution Days

Based on 32 resolved cases, 2023–2026

Rejection Statute Breakdown

5.3%

§101 Eligibility

22.1%

§102 Novelty

43.2%

§103 Obviousness

21.8%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
18261954	GENE ACTIVATION TARGETS FOR ENHANCED HUMAN T CELL FUNCTION	Non-Final OA	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18266093	COMPOSITIONS AND METHODS FOR GENE EDITING WITH WOOLLY MAMMOTH ALLELES	Non-Final OA	PRESIDENT AND FELLOWS OF HARVARD COLLEGE
18725696	USE OF IMMUNOSUPPRESSION TO ENABLE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS	Non-Final OA	The Board of Trustees of the Leland Stanford Junior University
17948382	METHODS OF CONTROLLING ANTIBODY HETEROGENEITY	Non-Final OA	Regeneron Pharmaceuticals, Inc.
18250996	PSEUDOTYPED PARTICLES, MODIFIED CELLS, RELATED COMPOSITIONS, AND RELATED METHODS	Final Rejection	CHILDREN'S HOSPITAL MEDICAL CENTER
18444107	METHODS AND COMPOSITIONS FOR ADMINISTERING OTOFERLIN DUAL VECTOR SYSTEMS	Non-Final OA	Decibel Therapeutics, Inc.
18041873	Use of Amylase or Maltose to Treat or Prevent Neurodegeneration	Non-Final OA	St. Jude Children's Research Hospital, Inc.
17797633	METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS	Non-Final OA	ASKBIO INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy